Later studies led to identifying and cloning the mammalian target of rapamycin, mTOR (mammalian Target of Rapamycin), which, along with its subsequent downstream targets, have emerged as candidates for cancer therapies [8,9]. This evidence concerns the gene MTOR and cancer.